SK4712003A3 - Nucleic acids encoding BAFF-R receptor, polypeptides BAFF-R and pharmaceutical compositions comprising same - Google Patents

Info

Publication number

SK4712003A3

SK4712003A3 SK471-2003A SK4712003A SK4712003A3 SK 4712003 A3 SK4712003 A3 SK 4712003A3 SK 4712003 A SK4712003 A SK 4712003A SK 4712003 A3 SK4712003 A3 SK 4712003A3

Authority

SK

Slovakia

Prior art keywords

baff

seq

protein

nucleic acid

polypeptide

Prior art date

2000-09-18

Links

• Espacenet
• Global Dossier
• Discuss

• 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 277
• 102000039446 nucleic acids Human genes 0.000 title claims abstract description 245
• 108020004707 nucleic acids Proteins 0.000 title claims abstract description 245
• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 174
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 154
• 229920001184 polypeptide Polymers 0.000 title claims abstract description 147
• 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 title claims abstract description 47
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
• 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 title claims abstract 42
• 238000000034 method Methods 0.000 claims abstract description 189
• 230000001363 autoimmune Effects 0.000 claims abstract description 12
• 231100000588 tumorigenic Toxicity 0.000 claims abstract description 10
• 230000000381 tumorigenic effect Effects 0.000 claims abstract description 10
• 210000004027 cell Anatomy 0.000 claims description 277
• 108090000623 proteins and genes Proteins 0.000 claims description 207
• 102000004169 proteins and genes Human genes 0.000 claims description 139
• 235000018102 proteins Nutrition 0.000 claims description 114
• 108020004414 DNA Proteins 0.000 claims description 111
• 150000001875 compounds Chemical class 0.000 claims description 108
• 239000000523 sample Substances 0.000 claims description 97
• 230000000694 effects Effects 0.000 claims description 96
• 125000003729 nucleotide group Chemical group 0.000 claims description 86
• 239000002773 nucleotide Substances 0.000 claims description 83
• 235000001014 amino acid Nutrition 0.000 claims description 69
• 150000001413 amino acids Chemical group 0.000 claims description 64
• 239000013598 vector Substances 0.000 claims description 63
• 230000027455 binding Effects 0.000 claims description 52
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 49
• 102000037865 fusion proteins Human genes 0.000 claims description 49
• 108020001507 fusion proteins Proteins 0.000 claims description 49
• 239000002299 complementary DNA Substances 0.000 claims description 44
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 41
• 230000000295 complement effect Effects 0.000 claims description 32
• 238000011282 treatment Methods 0.000 claims description 31
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 26
• 230000001404 mediated effect Effects 0.000 claims description 24
• 206010028980 Neoplasm Diseases 0.000 claims description 19
• 241001529936 Murinae Species 0.000 claims description 18
• 230000002776 aggregation Effects 0.000 claims description 16
• 238000004220 aggregation Methods 0.000 claims description 16
• 239000013068 control sample Substances 0.000 claims description 12
• 208000023275 Autoimmune disease Diseases 0.000 claims description 10
• 239000002253 acid Substances 0.000 claims description 10
• 230000008859 change Effects 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 10
• 150000007513 acids Chemical class 0.000 claims description 9
• 239000013610 patient sample Substances 0.000 claims description 9
• 235000004279 alanine Nutrition 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
• 230000004952 protein activity Effects 0.000 claims description 7
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
• 210000004698 lymphocyte Anatomy 0.000 claims description 6
• 210000001236 prokaryotic cell Anatomy 0.000 claims description 6
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 4
• 230000002829 reductive effect Effects 0.000 claims description 4
• 239000013642 negative control Substances 0.000 claims description 2
• 238000000159 protein binding assay Methods 0.000 claims description 2
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 4
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 4
• 230000000979 retarding effect Effects 0.000 claims 3
• 239000003814 drug Substances 0.000 abstract description 45
• 239000000203 mixture Substances 0.000 abstract description 28
• 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 668
• 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 627
• 230000014509 gene expression Effects 0.000 description 104
• 239000003795 chemical substances by application Substances 0.000 description 66
• 241000282414 Homo sapiens Species 0.000 description 65
• 239000012634 fragment Substances 0.000 description 65
• 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 64
• 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 64
• 238000012360 testing method Methods 0.000 description 61
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 60
• 108020004999 messenger RNA Proteins 0.000 description 60
• 201000010099 disease Diseases 0.000 description 56
• 125000003275 alpha amino acid group Chemical group 0.000 description 55
• 229940024606 amino acid Drugs 0.000 description 53
• 241001465754 Metazoa Species 0.000 description 42
• 230000000692 anti-sense effect Effects 0.000 description 42
• 238000003752 polymerase chain reaction Methods 0.000 description 40
• 239000013604 expression vector Substances 0.000 description 39
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
• 238000009396 hybridization Methods 0.000 description 37
• 230000035772 mutation Effects 0.000 description 37
• 238000003556 assay Methods 0.000 description 36
• 229940079593 drug Drugs 0.000 description 36
• 239000013615 primer Substances 0.000 description 35
• 210000001519 tissue Anatomy 0.000 description 33
• 102000005962 receptors Human genes 0.000 description 31
• 108020003175 receptors Proteins 0.000 description 31
• 239000000047 product Substances 0.000 description 30
• 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 29
• 108091034117 Oligonucleotide Proteins 0.000 description 27
• 230000001105 regulatory effect Effects 0.000 description 27
• 210000000349 chromosome Anatomy 0.000 description 24
• 239000013612 plasmid Substances 0.000 description 24
• 125000000539 amino acid group Chemical group 0.000 description 23
• 239000012472 biological sample Substances 0.000 description 22
• 102000004190 Enzymes Human genes 0.000 description 21
• 108090000790 Enzymes Proteins 0.000 description 21
• 238000001514 detection method Methods 0.000 description 21
• 229940088598 enzyme Drugs 0.000 description 21
• 238000006243 chemical reaction Methods 0.000 description 20
• 102000047802 human TNFRSF13C Human genes 0.000 description 20
• 230000004927 fusion Effects 0.000 description 19
• 239000003446 ligand Substances 0.000 description 19
• 230000009261 transgenic effect Effects 0.000 description 19
• 108700019146 Transgenes Proteins 0.000 description 18
• 238000012216 screening Methods 0.000 description 18
• 238000006467 substitution reaction Methods 0.000 description 18
• 230000001225 therapeutic effect Effects 0.000 description 18
• 108091026890 Coding region Proteins 0.000 description 17
• 239000000872 buffer Substances 0.000 description 16
• 230000000875 corresponding effect Effects 0.000 description 16
• 238000003199 nucleic acid amplification method Methods 0.000 description 16
• 239000000126 substance Substances 0.000 description 16
• 230000001594 aberrant effect Effects 0.000 description 15
• 230000003321 amplification Effects 0.000 description 15
• 239000005557 antagonist Substances 0.000 description 15
• 238000007423 screening assay Methods 0.000 description 15
• 108060003951 Immunoglobulin Proteins 0.000 description 14
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
• 239000000556 agonist Substances 0.000 description 14
• 102000018358 immunoglobulin Human genes 0.000 description 14
• 230000003993 interaction Effects 0.000 description 14
• 239000012528 membrane Substances 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 102000003390 tumor necrosis factor Human genes 0.000 description 14
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• 230000004071 biological effect Effects 0.000 description 13
• 230000002401 inhibitory effect Effects 0.000 description 13
• 239000000463 material Substances 0.000 description 13
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
• 239000000499 gel Substances 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 230000002974 pharmacogenomic effect Effects 0.000 description 12
• 238000003259 recombinant expression Methods 0.000 description 12
• 102000053602 DNA Human genes 0.000 description 11
• 239000004698 Polyethylene Substances 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• -1 for example Proteins 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 108090000994 Catalytic RNA Proteins 0.000 description 10
• 102000053642 Catalytic RNA Human genes 0.000 description 10
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 229930182817 methionine Natural products 0.000 description 10
• 108091092562 ribozyme Proteins 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 230000002068 genetic effect Effects 0.000 description 9
• 238000002744 homologous recombination Methods 0.000 description 9
• 230000006801 homologous recombination Effects 0.000 description 9
• 210000000987 immune system Anatomy 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 238000002703 mutagenesis Methods 0.000 description 9
• 231100000350 mutagenesis Toxicity 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 238000012163 sequencing technique Methods 0.000 description 9
• 238000011144 upstream manufacturing Methods 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 241000588724 Escherichia coli Species 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 8
• 230000009471 action Effects 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 108091007433 antigens Proteins 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 239000011324 bead Substances 0.000 description 8
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 239000002953 phosphate buffered saline Substances 0.000 description 8
• 230000000069 prophylactic effect Effects 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 8
• 108020004705 Codon Proteins 0.000 description 7
• 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 7
• 238000000636 Northern blotting Methods 0.000 description 7
• 108020004511 Recombinant DNA Proteins 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• 230000001413 cellular effect Effects 0.000 description 7
• 239000012707 chemical precursor Substances 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 238000002405 diagnostic procedure Methods 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 230000003902 lesion Effects 0.000 description 7
• 239000003550 marker Substances 0.000 description 7
• 239000011159 matrix material Substances 0.000 description 7
• 230000004048 modification Effects 0.000 description 7
• 238000012986 modification Methods 0.000 description 7
• 238000010369 molecular cloning Methods 0.000 description 7
• 102000054765 polymorphisms of proteins Human genes 0.000 description 7
• 108091008146 restriction endonucleases Proteins 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
• 108700026244 Open Reading Frames Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 108010090804 Streptavidin Proteins 0.000 description 6
• 102000040945 Transcription factor Human genes 0.000 description 6
• 108091023040 Transcription factor Proteins 0.000 description 6
• 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 102000050326 human TNFSF13B Human genes 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 239000002987 primer (paints) Substances 0.000 description 6
• 238000011321 prophylaxis Methods 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 210000000952 spleen Anatomy 0.000 description 6
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 208000011691 Burkitt lymphomas Diseases 0.000 description 5
• 108091033380 Coding strand Proteins 0.000 description 5
• 102000005720 Glutathione transferase Human genes 0.000 description 5
• 108010070675 Glutathione transferase Proteins 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 102000018120 Recombinases Human genes 0.000 description 5
• 108010091086 Recombinases Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 229920002684 Sepharose Polymers 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000003200 chromosome mapping Methods 0.000 description 5
• 239000003184 complementary RNA Substances 0.000 description 5
• 238000009833 condensation Methods 0.000 description 5
• 230000005494 condensation Effects 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 210000004408 hybridoma Anatomy 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 210000000287 oocyte Anatomy 0.000 description 5
• 239000000816 peptidomimetic Substances 0.000 description 5
• 102000040430 polynucleotide Human genes 0.000 description 5
• 108091033319 polynucleotide Proteins 0.000 description 5
• 239000002157 polynucleotide Substances 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 4
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
• 108020005544 Antisense RNA Proteins 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 4
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 4
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 4
• 239000003155 DNA primer Substances 0.000 description 4
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 102000018697 Membrane Proteins Human genes 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 101710163270 Nuclease Proteins 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 210000001671 embryonic stem cell Anatomy 0.000 description 4
• 230000005714 functional activity Effects 0.000 description 4
• 238000001114 immunoprecipitation Methods 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 230000000284 resting effect Effects 0.000 description 4
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• 241000972773 Aulopiformes Species 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 108020004635 Complementary DNA Proteins 0.000 description 3
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
• 230000004568 DNA-binding Effects 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 206010064571 Gene mutation Diseases 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 108091092724 Noncoding DNA Proteins 0.000 description 3
• 108091005461 Nucleic proteins Chemical class 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 101150090155 R gene Proteins 0.000 description 3
• 108700008625 Reporter Genes Proteins 0.000 description 3
• 108010083644 Ribonucleases Proteins 0.000 description 3
• 102000006382 Ribonucleases Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 239000011543 agarose gel Substances 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 239000003797 essential amino acid Substances 0.000 description 3
• 235000020776 essential amino acid Nutrition 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000004957 immunoregulator effect Effects 0.000 description 3
• 238000007901 in situ hybridization Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 210000001161 mammalian embryo Anatomy 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000037353 metabolic pathway Effects 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000005022 packaging material Substances 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 235000019515 salmon Nutrition 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 230000001131 transforming effect Effects 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 108700026215 vpr Genes Proteins 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 206010001935 American trypanosomiasis Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 102000016605 B-Cell Activating Factor Human genes 0.000 description 2
• 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
• 208000037914 B-cell disorder Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 208000024699 Chagas disease Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 108020004394 Complementary RNA Proteins 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
• 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 2
• 241000283074 Equus asinus Species 0.000 description 2
• 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 2
• 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 2
• 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 2
• 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 2
• 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 2
• 108091029865 Exogenous DNA Proteins 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 206010071602 Genetic polymorphism Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 241000235058 Komagataella pastoris Species 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 239000012097 Lipofectamine 2000 Substances 0.000 description 2
• 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 2
• 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 2
• 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 208000021161 Plasma cell disease Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 208000007452 Plasmacytoma Diseases 0.000 description 2
• 108020005067 RNA Splice Sites Proteins 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 2
• 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 2
• 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 2
• 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 2
• 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 2
• 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 2
• 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 2
• 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 239000013060 biological fluid Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000005178 buccal mucosa Anatomy 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000011748 cell maturation Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000749 co-immunoprecipitation Methods 0.000 description 2
• 238000012761 co-transfection Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 230000000536 complexating effect Effects 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000036267 drug metabolism Effects 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 238000001976 enzyme digestion Methods 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 208000025750 heavy chain disease Diseases 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 102000056239 human TNFRSF13B Human genes 0.000 description 2
• 210000004754 hybrid cell Anatomy 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 239000012133 immunoprecipitate Substances 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 150000002540 isothiocyanates Chemical class 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 230000001589 lymphoproliferative effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 230000031864 metaphase Effects 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 239000002853 nucleic acid probe Substances 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 230000000771 oncological effect Effects 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 235000021251 pulses Nutrition 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 230000003252 repetitive effect Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 231100000004 severe toxicity Toxicity 0.000 description 2
• 229910001415 sodium ion Inorganic materials 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 238000003151 transfection method Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
• YNXICDMQCQPQEW-UHFFFAOYSA-N 1-naphthyl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CC=CC2=C1 YNXICDMQCQPQEW-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• GGYMDMAXRQASFI-UHFFFAOYSA-N 2-(1-methoxy-2,4-dioxopyrimidin-5-yl)acetic acid Chemical compound CON1C(=O)NC(=O)C(=C1)CC(=O)O GGYMDMAXRQASFI-UHFFFAOYSA-N 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
• IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
• GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
• WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 108020005224 Arylamine N-acetyltransferase Proteins 0.000 description 1
• 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 101150010738 CYP2D6 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 240000001432 Calendula officinalis Species 0.000 description 1
• 235000005881 Calendula officinalis Nutrition 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 229940123150 Chelating agent Drugs 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 108020001738 DNA Glycosylase Proteins 0.000 description 1
• 102000028381 DNA glycosylase Human genes 0.000 description 1
• 230000007067 DNA methylation Effects 0.000 description 1
• 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
• 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000702191 Escherichia virus P1 Species 0.000 description 1
• 108010046276 FLP recombinase Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 241000288105 Grus Species 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 108091027305 Heteroduplex Proteins 0.000 description 1
• 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000003939 Membrane transport proteins Human genes 0.000 description 1
• 108090000301 Membrane transport proteins Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 108010011756 Milk Proteins Proteins 0.000 description 1
• 102000014171 Milk Proteins Human genes 0.000 description 1
• 101100369989 Mus musculus Tnfaip3 gene Proteins 0.000 description 1
• 101000851433 Mus musculus Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
• 101000795168 Mus musculus Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108010035042 Osteoprotegerin Proteins 0.000 description 1
• 102000008108 Osteoprotegerin Human genes 0.000 description 1
• 238000010222 PCR analysis Methods 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 241000577979 Peromyscus spicilegus Species 0.000 description 1
• 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010066717 Q beta Replicase Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 241000223892 Tetrahymena Species 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 229920004929 Triton X-114 Polymers 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
• 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
• ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
• 240000006677 Vicia faba Species 0.000 description 1
• 235000010749 Vicia faba Nutrition 0.000 description 1
• 235000002098 Vicia faba var. major Nutrition 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• RJZZTNAWUTTWMJ-WYIOVZGUSA-N [(2r,3s,5s)-5-amino-2-[2-(4-methoxyphenyl)-2,2-diphenylethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphonamidous acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C[C@@H]1[C@@H](OP(N)O)C[C@](N)(N2C(NC(=O)C(C)=C2)=O)O1 RJZZTNAWUTTWMJ-WYIOVZGUSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 229940033495 antimalarials Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 238000000211 autoradiogram Methods 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 239000005082 bioluminescent agent Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 125000002680 canonical nucleotide group Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000004656 cell transport Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000014107 chromosome localization Effects 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 208000035850 clinical syndrome Diseases 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 230000002153 concerted effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 150000001982 diacylglycerols Chemical class 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000003631 expected effect Effects 0.000 description 1
• 239000011536 extraction buffer Substances 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 238000012254 genetic linkage analysis Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 239000012145 high-salt buffer Substances 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008086 immune related sensitivity Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 230000036046 immunoreaction Effects 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000891 luminescent agent Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 210000003519 mature b lymphocyte Anatomy 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000009061 membrane transport Effects 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 235000021239 milk protein Nutrition 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000033607 mismatch repair Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 210000000472 morula Anatomy 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 101150029137 mutY gene Proteins 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 238000011330 nucleic acid test Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
• HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 230000010399 physical interaction Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 229940076376 protein agonist Drugs 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 229940048086 sodium pyrophosphate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 238000003161 three-hybrid assay Methods 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 238000003160 two-hybrid assay Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1